Health
Voruciclib Alone, Plus Sotorasib or Adagrasib, Shows Preliminary Potency Against KRAS+ Cancers – OncLive
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant…
The CDK9 inhibitor voruciclib demonstrated early activity as a single agent in KRAS-mutant cancer cell lines, and synergistically inhibited growth of KRAS-mutant cancers when used in combination with sotorasib (AMG 510) and adagrasib in preclinical models, according to findings presented during Week 1 of the 2021 AACR Virtual Annual Meeting.1,2
The early results showed that voruciclib led to a rapid decrease in the phosphorylation of proteins that promote MYC transcription and quickly decreases…
-
General23 hours agoGymnastics club in Berwick shuts down following child safety complaint
-
General17 hours agoAshes engulfed by fresh DRS controversy as TV umpire gives Jamie Smith out despite RTS ‘murmur’
-
General20 hours ago‘Mother’s Day’ solar storm squeezed Earth’s plasmasphere to one-fifth its size
-
Noosa News21 hours agoMeticulously crafted home in heart of Noosa Heads